ClinicalTrials.gg
Not yet recruitingNCT07675876CSUpdated Jul 1, 2026

Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer

A Phase 1 interventional study of Cromolyn Sodium in Locally Advanced Non-Small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Carcinex Inc. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Carcinex Inc · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Adenocarcinoma of Lung with a site in United States — 16 open to participants now, 31 under way, 2 of them phase 3. Adenocarcinoma of Lung · United States.

Planned enrollment
156th of 179
10 · median 50
Started
2026
with 2 others
Phase 1
46 of 206
6 open now
Primary completion
2027-06
later than 13 of 30 live
Registered
205th of 206
by date

Among the 206 studies in Adenocarcinoma of Lung with a site in United States, this one is the 156th largest by planned enrollment of the 179 interventional ones that give a count, is one of 3 that started in 2026, is one of 46 in phase 1, reaches primary completion later than 13 of the 30 other live ones, and was the 205th registered.

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 79 are open to participants now.

Browse Adenocarcinoma of Lung studies →

Open to participants now

16 of the 206 studies in Adenocarcinoma of Lung with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Adenocarcinoma of Lung studies recruiting now, 36 (62%) set no upper age limit and 10 (17%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Adenocarcinoma of Lung with a site in United States, or all of them as a file.
02

Study summary

Brief Summary

This prospective, open-label pilot study is designed to evaluate the safety, tolerability, feasibility, and preliminary clinical activity of inhaled cromolyn sodium administered by dry powder inhalation in participants with locally advanced lung cancer.

Cromolyn sodium is an FDA-approved mast cell stabilizer with an established safety profile in respiratory disease. Increasing evidence suggests that inflammatory signaling, mast cell activation, and stromal remodeling contribute to tumor progression, immune dysregulation, and resistance to therapy within the lung tumor microenvironment. Modulation of these pathways may represent a novel therapeutic strategy in lung cancer.

Approximately 5 to 10 participants with locally advanced lung cancer will receive inhaled cromolyn sodium according to the study protocol. Participants will undergo clinical assessments, safety monitoring, laboratory evaluations, and radiographic imaging in accordance with protocol-defined procedures and standard oncologic care.

The primary objective of this pilot study is to evaluate the safety, tolerability, and feasibility of inhaled Cromolyn sodium administration in this patient population. Secondary objectives include exploratory assessment of radiographic response, clinical outcomes, biomarker trends, and potential signals of biological activity. Data generated from this study are intended to support the development of future clinical investigations evaluating the role of mast cell stabilization and tumor microenvironment modulation in lung cancer.

Read the detailed description

Scientific Background and Rationale

Lung cancer remains a leading cause of cancer-related mortality worldwide despite substantial advances in molecularly targeted therapies, immunotherapy, radiation therapy, and multimodality treatment approaches. Increasing evidence indicates that, in addition to intrinsic tumor biology, the tumor microenvironment plays a critical role in disease progression, immune evasion, therapeutic resistance, and metastatic dissemination. Consequently, there is growing interest in therapeutic strategies designed to modulate tumor-associated inflammatory and stromal processes that contribute to cancer progression.

Mast cells are resident immune cells that participate in both innate and adaptive immune responses and are increasingly recognized as important components of the tumor microenvironment. In lung cancer, mast cell infiltration has been observed within both primary tumor tissue and surrounding stromal compartments. Experimental and translational studies have suggested that mast cells may contribute to tumor-associated inflammation through the release of cytokines, chemokines, growth factors, angiogenic mediators, and proteolytic enzymes capable of influencing immune regulation, angiogenesis, extracellular matrix remodeling, and cellular proliferation.

Cromolyn sodium is an FDA-approved mast cell stabilizing agent with a long-established clinical safety profile following inhalational administration for allergic respiratory disorders. The drug inhibits mast cell degranulation and reduces the release of multiple inflammatory mediators involved in downstream immune and inflammatory signaling pathways. In addition to its effects on mast cells, preclinical investigations have suggested broader effects on inflammatory processes involving macrophages, eosinophils, neutrophils, and other immune-regulatory cell populations implicated in tumor-associated inflammation.

Preclinical studies evaluating mast cell inhibition and modulation of inflammatory signaling pathways have generated interest in the potential role of tumor microenvironment-directed therapeutic strategies in solid tumors. Although the clinical significance of these observations remains uncertain, available experimental data provide a biologically plausible rationale for exploratory clinical investigation of cromolyn sodium in lung cancer.

The pulmonary route of administration offers additional scientific rationale for evaluation in this setting. Inhaled drug delivery permits direct deposition of therapeutic agents within the respiratory tract and may facilitate local exposure within pulmonary tissues while limiting systemic drug exposure. Administration by dry powder inhaler may provide efficient pulmonary delivery and represents a practical, non-invasive method of drug administration that can be implemented in both clinical and home-based settings.

Cromolyn sodium has demonstrated a favorable safety profile during decades of clinical use. Systemic absorption following inhalation is limited, systemic toxicity is uncommon, and the drug is not associated with many of the adverse effects characteristic of conventional cytotoxic anticancer therapies. Nevertheless, the use of inhaled cromolyn sodium for the treatment of lung cancer remains investigational and has not been established as safe or effective for this indication.

Given the established clinical safety profile of inhaled cromolyn sodium, its biologic activity as a mast cell stabilizer, the emerging understanding of inflammatory and stromal mechanisms in lung cancer progression, and the potential advantages of localized pulmonary drug delivery, a pilot clinical investigation is warranted to evaluate the safety, feasibility, tolerability, and preliminary clinical activity of inhaled cromolyn sodium in participants with locally advanced lung cancer.

Safety Considerations

Participants enrolled in this study will undergo protocol-defined safety monitoring throughout the treatment and follow-up periods. Safety assessments will include evaluation of treatment-emergent adverse events, respiratory symptoms, hypersensitivity reactions, clinically significant laboratory abnormalities, and other changes in clinical status. Given the investigational nature of this treatment approach, ongoing safety surveillance will be conducted throughout study participation.

03

Conditions studied

  • Locally Advanced Non-Small Cell Lung Cancer
  • Lung Adenocarcinoma

Keywords

  • local advanced lung cancer
  • Stage 3 lung cancer
  • Lung Adenocarcinoma
  • Cromolyn Sodium
  • Dry Powder Inhaler(DPI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with local advanced stage 3 lung cancer or lung adenocarcinoma will be eligible for the study only if they meet the following criteria:

  • Provide written prior to screening.
  • Male or female patients, age ≥ 18 years
  • Histological- or cytological-confirmed diagnosis of Lung cancer
  • Previous tumor scan location in lung

Exclusion criteria

Exclusion Criteria:

  • Treatment with another drug, biological agent, or device within 4 weeks (6 weeks for biological agents) before screening or 5 half-lives of study agent, whichever is longer.
  • Patients with known pericardial effusion
  • Patients with active infection or serious concomitant systemic disorder (for example, heart failure) incompatible with the study (at the discretion of the Investigator)
  • Planned concomitant participation in another clinical trial of an experimental agent, vaccine, or device.
  • Patients with any other medical condition that in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in or completing the study.
  • Known allergy or history of serious adverse event with Cromolyn Sodium
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Inhaled Cromolyn Sodium

    Participants with locally advanced lung cancer will receive cromolyn sodium administered by oral inhalation using a dry powder inhaler according to the study protocol.

    Drug: Cromolyn Sodium

Interventions

  • Cromolyn sodium administered by oral inhalation using a dry powder inhaler. Treatment will be administered according to the protocol-defined dosing schedule throughout the study period.

    Also known as: Sodium Cromoglycate

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Inhaled Cromolyn Sodium

    Incidence, severity, and frequency of treatment-emergent adverse events and serious adverse events during study participation.

    Time frame: Up to 12 months

Secondary outcomes

  1. Radiographic Tumor Response

    Exploratory assessment of changes in tumor burden based on clinically obtained imaging studies.

    Time frame: Baseline through 12 months

  2. Feasibility of Treatment Administration

    Assessment of participant completion of protocol-defined treatment and study procedures.

    Time frame: Up to 12 months

07

Study locations

2 sites
  • In home ttreatment
    Denver, Colorado 80220-4425, United States
  • Treated at home
    Denver, Colorado 80220-4425, United States
08

References and documents

Publications

  • Abd-Elaziz K, Oude Elberink H, Diamant Z. Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow(R) nebulizer. Eur Clin Respir J. 2020 Aug 20;7(1):1809083. doi: 10.1080/20018525.2020.1809083. PubMed 32944204 ↗
  • Hemmati AA, Nazari Z, Motlagh ME, Goldasteh S. The role of sodium cromolyn in treatment of paraquat-induced pulmonary fibrosis in rat. Pharmacol Res. 2002 Sep;46(3):229-34. doi: 10.1016/s1043-6618(02)00122-6. PubMed 12220965 ↗
  • Larsson K, Larsson BM, Sandstrom T, Sundblad BM, Palmberg L. Sodium cromoglycate attenuates pulmonary inflammation without influencing bronchial responsiveness in healthy subjects exposed to organic dust. Clin Exp Allergy. 2001 Sep;31(9):1356-68. doi: 10.1046/j.1365-2222.2001.01193.x. PubMed 11591185 ↗
  • Blumenthal MN, Selcow J, Spector S, Zeiger RS, Mellon M. A multicenter evaluation of the clinical benefits of cromolyn sodium aerosol by metered-dose inhaler in the treatment of asthma. J Allergy Clin Immunol. 1988 Apr;81(4):681-7. doi: 10.1016/0091-6749(88)91038-x. PubMed 3128589 ↗
  • Dreyer CJ. Fluoridation: a review of the 1976/1977 literature. J Dent Assoc S Afr. 1979 Mar;34(3):145-54. No abstract available. PubMed 397628 ↗
  • Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst. 2006 Dec 20;98(24):1806-18. doi: 10.1093/jnci/djj498. PubMed 17179482 ↗
  • Moroni M, Porta C, Gualtieri G, Nastasi G, Tinelli C. Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients. Br J Cancer. 1996 Jul;74(2):309-11. doi: 10.1038/bjc.1996.358. PubMed 8688342 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2026; primary completion for Jun 2027, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 30, 2026
StartEst.
Aug 2026
Primary completionEst.
Jun 2027
CompletionEst.
Aug 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07675876
Lead sponsor
Carcinex Inc
Responsible party
Svitlana Nesterenko (Nurse Practitioner- MSN, ACPC-C, Carcinex Inc) — Principal investigator
First posted
Jun 30, 2026
Start date
Aug 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Svitlana Nesterenko, AGCP-Nurse Practitioner
Contact
nesterenko13@gmail.com
7204721934
Charles CEO
Contact
charles@carcinex.org
303-875-7402
Charles Owen
study director · Carcinex Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cromolyn

Start the discussion